Collegium Pharmaceutical Inc
COLL30.105USD
+0.035+0.12%
Market hours （ET）Quotes delayed by 15 min
967.33MMarket Cap
22.04P/E TTM
More Details of Collegium Pharmaceutical Inc Company
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients. Its portfolio also includes Jornay PM.
Company Info
Ticker SymbolCOLL
Company nameCollegium Pharmaceutical Inc
IPO dateMay 07, 2015
CEOMr. Vikram Karnani
Number of employees357
Security typeOrdinary Share
Fiscal year-endMay 07
Address100 Technology Center Dr
CitySTOUGHTON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02072-4710
Phone17817133699
Websitehttps://www.collegiumpharma.com/
Ticker SymbolCOLL
IPO dateMay 07, 2015
CEOMr. Vikram Karnani
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Vikram Karnani
Mr. Vikram Karnani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.97K
--
Mr. David Dieter
Mr. David Dieter
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
68.45K
--
Ms. Colleen Tupper
Ms. Colleen Tupper
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
42.18K
-37.97%
Mr. Gino Santini
Mr. Gino Santini
Independent Chairman of the Board
Independent Chairman of the Board
35.23K
+38.49%
Dr. Rita J. Balice-Gordon, Ph.D.
Dr. Rita J. Balice-Gordon, Ph.D.
Independent Director
Independent Director
33.77K
+40.84%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
22.52K
+76.94%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Director
Independent Director
19.58K
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Dr. John A. Fallon, M.D.
Dr. John A. Fallon, M.D.
Independent Director
Independent Director
--
--
Ms. Jane Gonnerman
Ms. Jane Gonnerman
Executive Vice President - Strategy and Corporate Development
Executive Vice President - Strategy and Corporate Development
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Vikram Karnani
Mr. Vikram Karnani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.97K
--
Mr. David Dieter
Mr. David Dieter
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
68.45K
--
Ms. Colleen Tupper
Ms. Colleen Tupper
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
42.18K
-37.97%
Mr. Gino Santini
Mr. Gino Santini
Independent Chairman of the Board
Independent Chairman of the Board
35.23K
+38.49%
Dr. Rita J. Balice-Gordon, Ph.D.
Dr. Rita J. Balice-Gordon, Ph.D.
Independent Director
Independent Director
33.77K
+40.84%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
22.52K
+76.94%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Nucynta IR
75.06M
42.23%
Xtampza ER
51.66M
29.06%
Jomay PM
28.54M
16.06%
Belbuca
27.42M
15.42%
Nucynta ER
19.69M
11.07%
Symproic
2.81M
1.58%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Nucynta IR
75.06M
42.23%
Xtampza ER
51.66M
29.06%
Jomay PM
28.54M
16.06%
Belbuca
27.42M
15.42%
Nucynta ER
19.69M
11.07%
Symproic
2.81M
1.58%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
15.05%
Rubric Capital Management LP
9.33%
Eventide Asset Management, LLC
8.21%
The Vanguard Group, Inc.
6.97%
Renaissance Technologies LLC
5.03%
Other
55.41%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
15.05%
Rubric Capital Management LP
9.33%
Eventide Asset Management, LLC
8.21%
The Vanguard Group, Inc.
6.97%
Renaissance Technologies LLC
5.03%
Other
55.41%
Shareholder Types
Shareholders
Proportion
Investment Advisor
59.13%
Investment Advisor/Hedge Fund
31.78%
Hedge Fund
20.75%
Research Firm
3.18%
Individual Investor
1.79%
Pension Fund
1.21%
Bank and Trust
0.45%
Sovereign Wealth Fund
0.41%
Venture Capital
0.07%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
511
38.19M
118.82%
-4.98M
2025Q1
528
38.32M
119.23%
-5.70M
2024Q4
520
38.61M
122.59%
-6.60M
2024Q3
498
39.90M
123.83%
-6.67M
2024Q2
486
41.00M
125.33%
-4.08M
2024Q1
464
41.14M
125.78%
-3.32M
2023Q4
434
40.31M
123.54%
-3.32M
2023Q3
425
39.87M
114.82%
-4.18M
2023Q2
428
40.45M
116.96%
-4.39M
2023Q1
425
40.62M
117.50%
-1.29M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
4.84M
15.05%
-111.68K
-2.26%
Mar 31, 2025
Rubric Capital Management LP
3.00M
9.33%
+650.00K
+27.66%
Mar 31, 2025
Eventide Asset Management, LLC
2.64M
8.21%
+845.00
+0.03%
Mar 31, 2025
The Vanguard Group, Inc.
2.24M
6.97%
-36.10K
-1.59%
Mar 31, 2025
Renaissance Technologies LLC
1.62M
5.03%
-45.50K
-2.74%
Mar 31, 2025
Principal Global Investors (Equity)
1.57M
4.89%
-71.69K
-4.36%
Mar 31, 2025
Emerald Advisers LLC
1.40M
4.36%
+19.31K
+1.40%
Mar 31, 2025
State Street Global Advisors (US)
1.38M
4.28%
-62.15K
-4.32%
Mar 31, 2025
Fuller & Thaler Asset Management Inc.
1.37M
4.27%
+19.57K
+1.45%
Mar 31, 2025
Invesco Advisers, Inc.
953.91K
2.97%
-27.98K
-2.85%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Invesco Pharmaceuticals ETF
2.71%
Invesco Biotechnology & Genome ETF
2.67%
SPDR S&P Pharmaceuticals ETF
1.53%
Ballast Small/Mid Cap ETF
1.34%
ETC 6 Meridian Small Cap Equity ETF
1.16%
Invesco S&P SmallCap 600 GARP ETF
1.13%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.09%
VictoryShares Small Cap Free Cash Flow ETF
0.83%
Invesco S&P SmallCap 600 Pure Growth ETF
0.71%
Invesco S&P SmallCap Health Care ETF
0.68%
View more
Invesco Pharmaceuticals ETF
Proportion2.71%
Invesco Biotechnology & Genome ETF
Proportion2.67%
SPDR S&P Pharmaceuticals ETF
Proportion1.53%
Ballast Small/Mid Cap ETF
Proportion1.34%
ETC 6 Meridian Small Cap Equity ETF
Proportion1.16%
Invesco S&P SmallCap 600 GARP ETF
Proportion1.13%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.09%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.83%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion0.71%
Invesco S&P SmallCap Health Care ETF
Proportion0.68%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
